Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental cancer drug trial halted early – what we know

NCT ID NCT05578092

Terminated Disease control Sponsor: Mirati Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS-MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial was terminated early, so it did not reach later phases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MRTX0902 (SOS1 inhibitor) and adagrasib (KRAS G12C inhibitor)

What this could lead to

If successful, this could point toward a new treatment option for certain advanced cancers with specific gene mutations.

What could go wrong

This was a very early (Phase 1) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer colorectal neoplasm neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR COLO-RECTAL CANCER NON-SMALL-CELL LUNG CANCER SOLID TUMOR

Contacts and locations

Locations

  • Local Institution - 001-101

    Nashville, Tennessee, 37203, United States

  • Local Institution - 001-102

    Nashville, Tennessee, 37203, United States

  • Local Institution - 001-103

    Baltimore, Maryland, 21287, United States

  • Local Institution - 001-104

    Fairfax, Virginia, 22031, United States

  • Local Institution - 001-105

    Seattle, Washington, 98109, United States

  • Local Institution - 001-106

    Cincinnati, Ohio, 45219-2364, United States

  • Local Institution - 001-107

    Houston, Texas, 77030, United States

  • Local Institution - 001-108

    New Haven, Connecticut, 06520, United States

  • Local Institution - 001-109

    Portland, Oregon, 97239-3011, United States

  • Local Institution - 001-110

    Rochester, Minnesota, 55905-0001, United States

  • Local Institution - 001-111

    Orlando, Florida, 32827-7400, United States

  • Local Institution - 001-112

    Dallas, Texas, 75246-2003, United States

  • Local Institution - 001-114

    Rio Piedras, 00935, Puerto Rico

  • Local Institution - 001-115

    Hackensack, New Jersey, 07601-2191, United States

  • Local Institution - 001-116

    Pittsburgh, Pennsylvania, 15232, United States

  • Local Institution - 001-119

    Newark, Delaware, 19713-2055, United States

  • Local Institution - 001-122

    Fort Worth, Texas, 76104-2154, United States

  • Local Institution - 001-123

    Tyler, Texas, 75708-3154, United States